To determine the effect of a sudden decrease in estrogen levels via bilateral oophorectomy on serum turnover markers and to examine their correlation with bone mineral density (BMD).
This study included 51 women who had regular menses preoperatively and underwent bilateral oophorectomy for benign reasons. These women did not have any systemic disease or drug use that would influence bone metabolism. For each woman, spine and femur BMD were measured preoperatively and sixth months after surgery. Serum C-terminal telopeptide (CTX) and bone alkaline phosphatase (BAP) were measured preoperatively and at the first and sixth months after surgery. Correlations between bone turnover markers and BMD were pre- and post-operatively analyzed.
The mean serum CTX and BAP concentrations at the first and sixth postoperative months were significantly higher compared to the preoperative measurements (p = 0.001). Spine BMD values at the sixth postoperative month was significantly lower compared to preoperative period (p = 0.0001). There was a significant negative correlation between spine BMD values and BAP levels both in the preoperative period and at the sixth postoperative month (r = −0.407, p = 0.001), whereas a significant positive correlation between serum CTX and BAP was noted at this time periods (r = 0.615, p < 0.001).
The results of this study showed that serum BAP and CTX levels rapidly increase in women after bilateral oophorectomy. Therefore, these markers (especially BAP) could be useful in the evaluation of osteoporosis risk in the early period of surgical menopause.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Obstetrics and Gynecology and Reproductive Biology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Diagnosis, prophylaxis, and treatment of osteoporosis.Am J Med. 1993; 94: 646-650
- Introduction: postmenopausal osteoporosis as a major public health issue.J Manag Care Pharm. 2006; 12: 2-3
- Prevention of spinal osteoporosis in oophorectomised women.Lancet. 1980; 2: 1151-1154
- The chronological change of vertebral bone loss following oophorectomy using dual energy X-ray absorptiometry: the correlation with specific markers of bone metabolism.Maturitas. 1995; 22: 185-191
- Fracture risk following bilateral oophorectomy.J Clin Epidemiol. 1996; 49: 1111-1115
- Fundamentals and pitfalls of bone densitometry using dual-energy X-ray absorptiometry (DXA).Osteoporos Int. 2004; 15: 847-854
- Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study.BMJ. 1991; 303: 961-964
- Treatment of postmenopausal osteoporosis.Lancet. 2002; 359: 2018-2026
- Monitoring hormone replacement therapy by biochemical markers of bone metabolism in menopausal women.Postgrad Med J. 2002; 78: 727-731
- Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women.J Musculoskelet Neuronal Interact. 2004; 4: 50-63
- Automated and manual assays for urinary crosslinks of collagen: which assay to use?.Exp Clin Endocrinol Diabetes. 1998; 106: 143-148
- Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring.Mol Diagn Ther. 2008; 12: 157-170
- Concurrent assays of circulating bone Gla-protein and bone alkaline phosphatase: effects of sex, age, and metabolic bone disease.J Clin Endocrinol Metab. 1988; 66: 951-957
- Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study.J Clin Endocrinol Metab. 1997; 82: 2476-2482
- Minireview: osteoprotective action of estrogens is mediated by osteoclastic estrogen receptor-alpha.Mol Endocrinol. 2010; 24: 877-885
- Prophylaxis and treatment of osteoporosis.Am J Med. 1991; 90: 107-110
- Recent advances in bone biology provide insight into the pathogenesis of bone diseases.Lab Invest. 1999; 79: 83-94
- Change in serum undercarboxylated osteocalcin concentration in bilaterally oophorectomized women.Maturitas. 2007; 56: 288-296
- Serum androgen concentrations and bone mineral density in postmenopausal ovariectomized and non-ovariectomized women.Arq Bras Endocrinol Metab. 2009; 53: 1033-1039
- Bone loss rate in the lumbar spine: a comparison between natural and surgically induced menopause.Int J Gynaecol Obstet. 1996; 55: 153-159
- Bone resorption versus estrogen loss following oophorectomy and menopause.Maturitas. 2002; 43: 27-33
- Biochemical markers of bone turnover after surgical menopause and hormone replacement therapy.Bone. 1999; 25: 349-353
- Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.J Bone Miner Res. 1996; 11: 337-349
- An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation.Osteoporos Int. 2000; 11: 192-202
- Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women.Maturitas. 2003; 44: 259-265
- Bone resorption in post-menopausal women with normal and low BMD assessed with biochemical markers specific for telopeptide derived degradation products of collagen type I.Calcif Tissue Int. 2001; 69: 130-137
- Role of type I collagen C telopeptide, bone-specific alkaline phosphatase and osteocalcin in the assessment of bone status in postmenopausal women.J Obstet Gynaecol Res. 2009; 35: 152-159
Published online: June 27, 2011
Accepted: June 9, 2011
Received in revised form: May 5, 2011
Received: October 20, 2010
© 2011 Elsevier Ireland Ltd. Published by Elsevier Inc. All rights reserved.